<DOC>
	<DOCNO>NCT02582333</DOCNO>
	<brief_summary>Background : Taiwan one area high prevalence chronic hepatitis B ( CHB ) , many patient die hepatitis B virus ( HBV ) -related cirrhosis liver cancer lead cause death Taiwan many year . For effectively treat CHB , antiviral therapy CHB reimburse National Health Insurance Taiwan since 1998 , nucleos ( ) ide analogue ( NAs ) use patient active hepatitis B high viral load maximum duration three year . However , significant proportion patient suffer hepatitis B recurrence discontinuation NA therapy , hepatitis B recurrence may result liver cirrhosis liver cancer . To best current knowledge , condition NA therapy successfully discontinue without hepatitis recurrence remain largely unclear . Therefore , study design evaluate clinical virological change CHB patient stop NA therapy , find prognostic indicator may important basis stop NA therapy CHB patient future . Objectives : 1 . To access clinical virological change stop NA therapy 2 . To determine important prognostic indicator stop NA therapy Methods : In prospective cohort study , investigator plan recruit CHB patient indicate stop NA therapy outpatient clinic accord inclusion exclusion criterion study , clinical virological data collect routine clinic visit stop NA therapy . Prognostic factor analyze accord follow data : 1 . Patient characteristic : include age , sex , height , weight , waist circumference , history alcohol drinking , antiviral therapy history , hepatitis history , drug history . 2 . Blood test : During routine clinic visit blood test every 12 week hepatitis flare first 2 year stop NA therapy , liver function virological status test conduct analysis .</brief_summary>
	<brief_title>Clinical Course Study Chronic Hepatitis B After Nucleos ( ) Ide Analogue Therapy</brief_title>
	<detailed_description>Background : Taiwan one area high prevalence chronic hepatitis B ( CHB ) , many patient die hepatitis B virus ( HBV ) -related cirrhosis liver cancer lead cause death Taiwan many year . For effectively treat CHB , antiviral therapy CHB reimburse National Health Insurance Taiwan since 1998 , nucleos ( ) ide analogue ( NAs ) use patient active hepatitis B high viral load maximum duration three year . However , significant proportion patient suffer hepatitis B recurrence discontinuation NA therapy , hepatitis B recurrence may result liver cirrhosis liver cancer . To best current knowledge , condition NA therapy successfully discontinue without hepatitis recurrence remain largely unclear . Therefore , study design evaluate clinical virological change CHB patient stop NA therapy , find prognostic indicator may important basis stop NA therapy CHB patient future . Objectives : 1 . To access clinical virological change stop NA therapy 2 . To determine important prognostic indicator stop NA therapy Methods : In prospective cohort study , investigator plan recruit CHB patient indicate stop NA therapy outpatient clinic accord inclusion exclusion criterion study , clinical virological data collect routine clinic visit stop NA therapy . Prognostic factor analyze accord follow data : 1 . Patient characteristic : include age , sex , height , weight , waist circumference , history alcohol drinking , antiviral therapy history , hepatitis history , drug history . 2 . Blood test : During routine clinic visit blood test every 12 week hepatitis flare first 2 year stop NA therapy , liver function virological status test conduct analysis . Importance : To clinician treat chronic hepatitis B , study provide important data regard clinical course stop NA therapy , important prognostic indicator may determine . These finding could help clinicians decision make discontinuation NA therapy book follow-up schedule . To basic scientist , study provide virological change stop NA therapy , finding may help develop virological research .</detailed_description>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Age &gt; = 20 year old 2 . Chronic hepatitis B patient receive tenofovir entecavir first antiHBV therapy 3 . Patients receive nucleos ( ) ide analogue therapy &gt; 3 year reach stop criterion APASL ( HBeAg+ patient : HBeAg seroconversion &gt; 12 month ; HBeAg patient : HBV DNA undetectable &gt; 12 month ) 1 . History liver cirrhosis hepatocellular carcinoma 2 . Recipients liver transplantation 3 . Concurrent malignancy ( except curable skin cancer ) 4 . Concomitant use immunosuppressant 5 . Coinfection HCV , HDV , HIV</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>